Overview

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

Status:
Completed

Trial end date:
2020-09-07

Target enrollment:

Participant gender:

Summary

Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with T2DM (Type 2 Diabetes Mellitus) inadequately controlled with diet and exercise. Secondary Objectives: - To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison to placebo on glycemic control - To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison to placebo on body weight - To evaluate the safety of once-weekly injection of efpeglenatide

Phase:

Phase 3

Details

Lead Sponsor:

Hanmi Pharmaceutical Company Limited
Sanofi

Collaborator:

Sanofi

Treatments:

Efpeglenatide